Investigating epidemiological distribution (temporality and intensity) of respiratory pathogens following COVID-19 de-escalation process in Catalonia, September 2016-June 2021: Analysis of regional surveillance data.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

COVID-19*/epidemiology ; Influenza, Human*/epidemiology ; Respiratory Syncytial Virus, Human* ; Respiratory Tract Infections*/epidemiology; Child ; Humans ; Child, Preschool ; Spain/epidemiology ; SARS-CoV-2 ; Retrospective Studies ; Communicable Disease Control ; Parainfluenza Virus 1, Human ; Pandemics

Background: Following the low incidence rates of non-SARS-CoV-2 respiratory viruses registered during the strict lockdown enforced in the pandemic, a resurgence of several endemic viruses in Catalonia (Spain) was noted during the early summer of 2021.
Objectives: In this study, we investigated whether the circulation of non-SARS-CoV-2 respiratory viruses in Catalonia, assessed by Microbiological Reporting System of Catalonia (MRSC) and the Epidemiological Surveillance Network of Catalonia, was affected by the strict lockdown measures, as well as, the implication of the Coronavirus Disease 19 (COVID-19) de-escalation process in the late season outbreaks registered during the 2020-2021 season.
Study Design: A retrospective comparison of epidemic patterns in the respiratory viruses' incidence, using regional public health surveillance data from MRSC, was performed between weeks 26/2016 to week 27/2021. Data were expressed as the weekly total number of test positivity for individual viruses. A segmented negative binomial regression model was conducted, with two parameters included (level and trend) for each segment of the time series (2020 pre-lockdown, 2020 post-lockdown and 2021). Results were reported as a unit changed in the strict lockdown.
Results: A total of 51588 confirmed cases of the different respiratory viruses were included in the analysis, the majority were influenza cases (63.7%). An immediate reduction in the weekly number of cases was observed in 2020 after the COVID-19 outbreak for human adenovirus virus (HAdV) (β2 = -2.606; P <0.01), human parainfluenza virus (HPIV) (β2 = -3.023; P <0.01), influenza virus (IFV) (β2 = -1.259; P <0.01), but not for respiratory syncytial virus (RSV), where the number of cases remained unchanged. During 2020, a significant negative trend was found for RSV (β3 = -0.170, P <0.01), and a positive trend for HAdV (β3 = 0.075, P <0.01). During 2021, a significant reduction in the weekly number of cases was also observed for all respiratory viruses, and a borderline non-significant reduction for HPIV (β3 = -0.027; P = 0.086). Moreover, significant positive trends were found for each viral pathogen, except for influenza during 2020-2021 season, where cases remained close to zero. The respiratory viruses increased activity and their late season epidemic start particularly affected children under 6 years old.
Conclusions: Our data not only provides evidence that occurrence of different respiratory virus infections was affected by the strict lockdown taken against SARS-CoV-2 but it also shows a late resurgence of seasonal respiratory viruses' cases during the 2020-2021 season following the relaxation of COVID-19-targeted non-pharmaceutical interventions.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Guadalupe-Fernández et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

J Glob Antimicrob Resist. 2022 Mar;28:223-225. (PMID: 35074567)
J Clin Virol Plus. 2022 Feb;2(1):100060. (PMID: 35262033)
J Clin Lab Anal. 2022 Jan;36(1):e24151. (PMID: 34851526)
Vaccines (Basel). 2021 Jun 03;9(6):. (PMID: 34205119)
Lancet Microbe. 2020 Oct;1(6):e254-e262. (PMID: 33103132)
Children (Basel). 2021 Jun 28;8(7):. (PMID: 34203542)
West J Emerg Med. 2021 Oct 26;22(6):1262-1269. (PMID: 34787549)
Eur J Clin Microbiol Infect Dis. 2021 Nov;40(11):2389-2395. (PMID: 34347190)
Euro Surveill. 2021 Jul;26(29):. (PMID: 34296678)
J Infect. 2022 Jan;84(1):40-47. (PMID: 34757137)
Pediatr Infect Dis J. 2022 Feb 1;41(2):e46-e48. (PMID: 35017455)
Epidemics. 2021 Jun;35:100460. (PMID: 33838587)
J Pediatric Infect Dis Soc. 2016 Mar;5(1):7-13. (PMID: 26908486)
JAMA Netw Open. 2022 Feb 1;5(2):e2146175. (PMID: 35103792)
Front Microbiol. 2022 Jul 01;13:938372. (PMID: 35875547)
PLoS One. 2021 Feb 24;16(2):e0247200. (PMID: 33626106)
N Engl J Med. 2016 Jan 7;374(1):62-72. (PMID: 26735994)
Lancet. 2017 Sep 2;390(10098):946-958. (PMID: 28689664)
PLoS One. 2022 Aug 3;17(8):e0265288. (PMID: 35921317)
JAMA. 2020 May 26;323(20):2085-2086. (PMID: 32293646)
J Infect Dis. 2014 Jun 15;209(12):1873-81. (PMID: 24482398)
An Pediatr (Engl Ed). 2022 Apr;96(4):334-341. (PMID: 35609953)
Sci Rep. 2020 Jun 24;10(1):10246. (PMID: 32581261)
Am J Transplant. 2021 Oct;21(10):3481-3486. (PMID: 34624182)
J Clin Microbiol. 2011 Dec;49(12):4083-8. (PMID: 21998418)
Children (Basel). 2022 Jun 08;9(6):. (PMID: 35740785)
Clin Infect Dis. 2021 Nov 2;73(9):e2829-e2830. (PMID: 33594407)
J Med Virol. 2010 Jul;82(7):1282-90. (PMID: 20513097)
Viruses. 2021 Mar 10;13(3):. (PMID: 33802155)
PLoS One. 2011;6(10):e26047. (PMID: 22039434)
Rev Med Virol. 2023 Jan;33(1):e2365. (PMID: 35686619)
J Clin Virol. 2021 Apr;137:104795. (PMID: 33761423)
Diagnostics (Basel). 2021 Jun 13;11(6):. (PMID: 34199257)
Semin Respir Crit Care Med. 2016 Aug;37(4):586-602. (PMID: 27486739)
PLoS One. 2016 May 19;11(5):e0155589. (PMID: 27196110)
Curr Infect Dis Rep. 2020 Jan 24;22(1):3. (PMID: 31980966)
Pathology. 2022 Feb;54(1):120-122. (PMID: 34776245)
Infect Dis Rep. 2022 Jul 24;14(4):558-568. (PMID: 35893478)
Influenza Other Respir Viruses. 2016 Sep;10(5):394-403. (PMID: 27232677)
J Clin Microbiol. 2021 Feb 18;59(3):. (PMID: 33298613)
Am J Transplant. 2020 Dec;20(12):3681-3685. (PMID: 33264506)
Euro Surveill. 2022 May;27(19):. (PMID: 35551707)

Date Created: 20240209 Date Completed: 20240214 Latest Revision: 20240214

20240214

PMC10857536

10.1371/journal.pone.0285892

38335176